Govt asks pharma cos to stop advertising ECPs

Image
Press Trust of India New Delhi
Last Updated : Jan 20 2013 | 1:04 AM IST

The government has issued an advisory to all the marketers of oral emergency contraceptive pills (ECP) asking them not to advertise the product.

"Since drug advertising is not permitted under the existing rule, we have sent an advisory to all pharmaceutical companies making ECPs, asking them not to advertise their products through mass media," a source in the Health Ministry told PTI on condition of anonymity.

ECP drugs are to be taken within 72 hours of unprotected sex to avoid pregnancy. Emergency contraceptive pills are not scheduled drugs and can thus be bought over-the-counter, that is to say, without a prescription.

According to the information available, though around 15 companies are now producing ECPs in the country, Piramal Healthcare, Morepen, and Mankind together control over 80 per cent share in the segment.
    
The national health regulator Drug Controller General of India (DCGI) had earlier this year withdrawn the permission to advertise ECPs through print and electronic media as the ads did not convey the fact that the pills were to be consumed only in case of emergency.
    
But later, the Health Ministry had permitted it on condition that such ads should make the consumer aware of the side-effects. But recently the DCGI sent notices to three drug makers for showing the ads without addressing the concerns raised by the government.
    
"The three companies have been asked to respond to the notice within 14 days, failing which the DCGI would may take action against them," the source said.
    
The technical advisory body for drugs had also decided to frame guidelines on ads of ECPs following reports of side- effects in some cases due to indiscriminate use.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 25 2010 | 2:38 PM IST

Next Story